Lifesci Capital Reduces Earnings Estimates for Opus Genetics

Opus Genetics, Inc. (NASDAQ:IRD) – Analysts at Lifesci Capital decreased their Q1 2026 earnings per share (EPS) estimates for Opus Genetics in a research report issued on Tuesday, March 10th. Lifesci Capital analyst F. Brisebois now forecasts that the company will earn ($0.14) per share for the quarter, down from their previous estimate of ($0.13). Lifesci Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Opus Genetics’ current full-year earnings is ($1.22) per share. Lifesci Capital also issued estimates for Opus Genetics’ Q2 2026 earnings at ($0.13) EPS and FY2026 earnings at ($0.49) EPS.

Other equities research analysts have also recently issued reports about the stock. Brookline Capital Acquisition raised shares of Opus Genetics to a “strong-buy” rating in a research report on Monday, December 1st. Wall Street Zen raised shares of Opus Genetics from a “sell” rating to a “hold” rating in a research report on Sunday, March 1st. Wedbush increased their price target on shares of Opus Genetics from $8.00 to $10.00 and gave the stock an “outperform” rating in a research note on Thursday. Chardan Capital lifted their price target on shares of Opus Genetics from $9.00 to $11.00 and gave the company a “buy” rating in a report on Thursday. Finally, Piper Sandler started coverage on shares of Opus Genetics in a research note on Tuesday, November 25th. They set an “overweight” rating and a $7.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Opus Genetics has an average rating of “Buy” and an average price target of $9.25.

Opus Genetics Stock Up 3.9%

IRD opened at $5.03 on Friday. Opus Genetics has a 12 month low of $0.65 and a 12 month high of $5.30. The business has a 50-day moving average of $3.19 and a two-hundred day moving average of $2.32. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.23 and a quick ratio of 1.23. The stock has a market capitalization of $346.87 million, a price-to-earnings ratio of -6.13 and a beta of 0.45.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Occudo Quantitative Strategies LP acquired a new stake in shares of Opus Genetics in the fourth quarter worth $25,000. Comerica Bank acquired a new position in shares of Opus Genetics during the 1st quarter valued at $29,000. Virtu Financial LLC purchased a new stake in Opus Genetics during the 4th quarter worth $34,000. Raymond James Financial Inc. boosted its position in Opus Genetics by 95.6% during the 3rd quarter. Raymond James Financial Inc. now owns 22,508 shares of the company’s stock worth $37,000 after purchasing an additional 11,000 shares during the period. Finally, Johnson Investment Counsel Inc. acquired a new stake in Opus Genetics in the 4th quarter valued at $40,000. 14.97% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Opus Genetics

In other news, Director Cam Gallagher bought 83,000 shares of the firm’s stock in a transaction dated Monday, December 29th. The stock was acquired at an average price of $1.97 per share, for a total transaction of $163,510.00. Following the acquisition, the director owned 83,000 shares of the company’s stock, valued at $163,510. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 6.60% of the stock is owned by corporate insiders.

Key Stories Impacting Opus Genetics

Here are the key news stories impacting Opus Genetics this week:

• Positive Sentiment: Multiple firms raised price targets and reiterated positive ratings (supports upside momentum). Chardan raised its target to $11 with a Buy rating. Chardan price target raise
• Positive Sentiment: Wedbush boosted its target to $10 and kept an Outperform rating—another endorsement from a sell‑side shop. Wedbush price target raise
• Positive Sentiment: BTIG raised its price target to $12 (from $7) and maintained a Buy—adds to the cluster of higher targets that can drive investor interest. BTIG note
• Positive Sentiment: Clinical update: Opus provided progress on its Nyxol (oxymetazoline) clinical program (Phase 3 presbyopia/night‑vision studies), which is a near‑term catalyst investors watch for regulatory/market readthroughs. Clinical trial update
• Neutral Sentiment: H.C. Wainwright publicly remains constructive on Opus (keeps a Buy stance), which supports ongoing investor confidence even amid forecast changes. HC Wainwright buy rating
• Negative Sentiment: HC Wainwright cut near‑term EPS estimates across 2026 quarters and lowered FY2026 (to −$0.64) and FY2027/FY2028 forecasts substantially — this reflects a darker near‑term profitability outlook and could pressure the stock if clinical/operational progress stalls.
• Negative Sentiment: Lifesci Capital also trimmed Q1/Q2 and FY2026 EPS estimates (despite keeping a Strong‑Buy rating), signaling some analyst caution about timing or magnitude of revenue/cost assumptions.

About Opus Genetics

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.